Investigating how gut bacteria affect lymphoma treatment outcomes and immune response
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity
This study is looking at how the bacteria in your gut might affect how well treatment works for people with diffuse large B-cell lymphoma, and it hopes to find ways to personalize therapies based on your unique gut health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11015859 on NIH RePORTER |
What this research studies
This research explores the relationship between the gut microbiome and the treatment outcomes of patients with diffuse large B-cell lymphoma (DLBCL). By analyzing stool samples from 300 patients before, during, and after treatment, the study aims to understand how the composition of gut bacteria influences the body's immune response to lymphoma. The research employs advanced sequencing techniques to identify specific gut microbiome signatures that may correlate with treatment success or failure. This could lead to new strategies for improving lymphoma therapies based on individual microbiome profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with diffuse large B-cell lymphoma who are about to begin treatment.
Not a fit: Patients with lymphoma types other than diffuse large B-cell lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment approaches that enhance the effectiveness of lymphoma therapies.
How similar studies have performed: Previous research has shown promising results in understanding the role of the gut microbiome in cancer treatment outcomes, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Diefenbach, Catherine Sibyl — New York University School of Medicine
- Study coordinator: Diefenbach, Catherine Sibyl
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.